|
93
|
291
|
5oktC |
Crystal structure of human casein kinase i delta in complex with iwp-2 |
|
107
|
350
|
5oy4A |
Gsk3beta complex with n-(6-(3,4-dihydroxyphenyl)-1h-pyrazolo[3,4-b]pyridin-3-yl)acetamide |
|
99
|
347
|
5hlpA |
X-ray crystal structure of gsk3b in complex with brd3937 |
|
97
|
346
|
5f94A |
Crystal structure of gsk3b in complex with compound 15: 2-[(cyclopropylcarbonyl)amino]-n-(4-methoxypyridin-3-yl)pyridine-4-carboxamide |
|
98
|
348
|
5f95A |
Crystal structure of gsk3b in complex with compound 18: 2-[(cyclopropylcarbonyl)amino]-n-(4-phenylpyridin-3-yl)pyridine-4-carboxamide |
|
119
|
538
|
5ezvA |
X-ray crystal structure of amp-activated protein kinase alpha-2/alpha-1 rim chimaera (alpha-2(1-347)/alpha-1(349-401)/alpha-2(397-end) beta-1 gamma-1) co-crystallized with c2 (5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid) |
|
93
|
316
|
5eakA |
Optimization of microtubule affinity regulating kinase (mark) inhibitors with improved physical properties |
|
101
|
358
|
5airA |
Structural analysis of mouse gsk3beta fused with lrp6 peptide. |
|
97
|
332
|
4yomB |
Structure of sad kinase |
|
100
|
335
|
4ynzA |
Structure of the n-terminal domain of sad |
|
23
|
118
|
4yomA |
Structure of sad kinase |
|
105
|
294
|
4twcA |
2-benzamido-n-(1h-benzo[d]imidazol-2-yl)thiazole-4- carboxamide derivatives as potent inhibitors of ck1d/e |
|
98
|
292
|
4tn6A |
Ck1d in complex with inhibitor |
|
91
|
294
|
4tw9A |
Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of ck1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation |
|
96
|
540
|
4rerA |
Crystal structure of the phosphorylated human alpha1 beta2 gamma1 holo-ampk complex bound to amp and cyclodextrin |
|
100
|
493
|
4qfrA |
Structure of ampk in complex with cl-a769662 activator and staurosporine inhibitor |
|
85
|
540
|
4rewA |
Crystal structure of the non-phosphorylated human alpha1 beta2 gamma1 holo-ampk complex |
|
99
|
493
|
4qfgA |
Structure of ampk in complex with staurosporine inhibitor and in the absence of a synthetic activator |
|
78
|
340
|
4redA |
Crystal structure of human ampk alpha1 kd-aid with k43a mutation |
|
97
|
493
|
4qfsA |
Structure of ampk in complex with br2-a769662core activator and staurosporine inhibitor |
|
103
|
347
|
4pteA |
Structure of a carvoxamide compound (15) (n-[4-(isoquinolin-7-yl)pyridin-2-yl]cyclopropanecarboxamide) to gsk3b |
|
89
|
346
|
4ptcA |
Structure of a carboxamide compound (3) (2-{2-[(cyclopropylcarbonyl)amino]pyridin-4-yl}-4-oxo-4h-1lambda~4~,3-thiazole-5-carboxamide) to gsk3b |
|
99
|
347
|
4ptgA |
Structure of a carboxamine compound (26) (2-{2-[(cyclopropylcarbonyl)amino]pyridin-4-yl}-4-methoxypyrimidine-5-carboxamide) to gsk3b |
|
102
|
359
|
4nm0A |
Crystal structure of peptide inhibitor-free gsk-3/axin complex |
|
106
|
378
|
4nu1A |
Crystal structure of a transition state mimic of the gsk-3/axin complex bound to phosphorylated n-terminal auto-inhibitory ps9 peptide |
|
107
|
379
|
4nm3A |
Crystal structure of gsk-3/axin complex bound to phosphorylated n-terminal auto-inhibitory ps9 peptide |
|
104
|
360
|
4nm7A |
Crystal structure of gsk-3/axin complex bound to phosphorylated wnt receptor lrp6 e-motif |
|
108
|
361
|
4nm5A |
Crystal structure of gsk-3/axin complex bound to phosphorylated wnt receptor lrp6 c-motif |
|
94
|
291
|
4kbaA |
Ck1d in complex with 9-[3-(4-fluorophenyl)-1-methyl-1h-pyrazol-4-yl]-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine inhibitor |
|
95
|
291
|
4kbkA |
Ck1d in complex with (3s)-3-{4-[3-(4-fluorophenyl)-1-methyl-1h-pyrazol-4-yl]pyridin-2-yl}morpholine inhibitor |
|
92
|
291
|
4kb8A |
Ck1d in complex with 1-{4-[3-(4-fluorophenyl)-1-methyl-1h-pyrazol-4-yl]pyridin-2-yl}-n-methylmethanamine ligand |
|
98
|
292
|
4kbcA |
Ck1d in complex with {4-[3-(4-fluorophenyl)-1h-pyrazol-4-yl]pyridin-2-yl}methanol inhibitor |
|
96
|
348
|
4j1rA |
Crystal structure of gsk3b in complex with inhibitor 15r |
|
98
|
297
|
4jjrA |
A p21 crystal form of mammalian casein kinase 1 delta |
|
94
|
346
|
4iq6A |
Gsk-3beta with inhibitor 6-chloro-n-cyclohexyl-4-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-amine |
|
99
|
348
|
4j71A |
Crystal structure of gsk3b in complex with inhibitor 1r |
|
93
|
292
|
4hnfA |
Crystal structure of ck1d in complex with pf4800567 |
|
92
|
286
|
4hgtA |
Crystal structure of ck1d with compound 13 |
|
0
|
10
|
3qkkC |
Spirochromane akt inhibitors |
|
99
|
352
|
3q3bA |
6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3 inhibitors |
|
95
|
348
|
3pupA |
Structure of glycogen synthase kinase 3 beta (gsk3b) in complex with a ruthenium octasporine ligand (os1) |
|
27
|
100
|
3oseA |
Structure of the kinase associated domain 1 (ka1) from mark1 kinase |
|
0
|
10
|
3mv5C |
Crystal structure of akt-1-inhibitor complexes |
|
94
|
351
|
3m1sA |
Structure of ruthenium half-sandwich complex bound to glycogen synthase kinase 3 |
|
94
|
360
|
3l1sA |
3-aryl-4-(arylhydrazono)-1h-pyrazol-5-ones: highly ligand efficient and potent inhibitors of gsk3 |
|
101
|
315
|
3iecA |
Helicobacter pylori caga inhibits par1/mark family kinases by mimicking host substrates |
|
106
|
361
|
3i4bA |
Crystal structure of gsk3b in complex with a pyrimidylpyrrole inhibitor |
|
95
|
349
|
3gb2A |
Gsk3beta inhibitor complex |
|
98
|
349
|
3f88A |
Glycogen synthase kinase 3beta inhibitor complex |
|
98
|
350
|
3f7zA |
X-ray co-crystal structure of glycogen synthase kinase 3beta in complex with an inhibitor |
